Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

Incretin therapy has emerged as one of the most popular medications for type 2 diabetes. We have previously reported that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin attenuates neointima formation after vascular injury in non-diabetic mice. In the present study, we examined whether comb...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Biochem Biophys Rep
Auteurs principaux: Takahashi, Hiroyuki, Nomiyama, Takashi, Terawaki, Yuichi, Horikawa, Takeshi, Kawanami, Takako, Hamaguchi, Yuriko, Tanaka, Tomoko, Motonaga, Ryoko, Fukuda, Takashi, Tanabe, Makito, Yanase, Toshihiko
Format: Artigo
Langue:Inglês
Publié: Elsevier 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477163/
https://ncbi.nlm.nih.gov/pubmed/31032431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbrep.2019.100640
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires